MedCap AB (FRA:61MA) Stock Based Compensation: €0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:61MA MedCap AB FRA:61MA
81 GF Score
Price €48.24
GF Value €48.78
Valuation Fairly Valued
View Full Analysis

What is MedCap AB Stock Based Compensation?

MedCap AB FRA:61MA +4.46% 81 Stock Based Compensation is €0.0 Mil as of Jun. 2026. GuruFocus rates FRA:61MA with a GF Score™ of 81/100 and a GF Value™ of €48.78 (Fairly Valued).

MedCap AB's Stock Based Compensation for the three months ended in Jun. 2026 was €0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was €0.0 Mil.

MedCap AB Stock Based Compensation Related Terms

MedCap AB Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for MedCap AB's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedCap AB Stock Based Compensation Chart

MedCap AB Annual Data
Trend Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MedCap AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:61MA
81GF Score
MedCap AB FRA:61MA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedCap AB Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

What does a Stock Based Compensation of €0.0 Mil mean?
MedCap AB (FRA:61MA) has a Stock Based Compensation of €0.0 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for MedCap AB and its competitors.
Is MedCap AB's Stock Based Compensation too high?
MedCap AB's current Stock Based Compensation is €0.0 Mil. Overall, MedCap AB has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Stock Based Compensation compare to ABT and SYK?
MedCap AB's Stock Based Compensation of €0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for MedCap AB and its competitors. MedCap AB's current Stock Based Compensation is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (FRA:61MA) is currently considered Fairly Valued. The stock's GF Value™ is €48.78, compared to a current price of €48.24 — trading 1.1% below its estimated fair value. The current Stock Based Compensation is €0.0 Mil. MedCap AB's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For MedCap AB (FRA:61MA), the current Stock Based Compensation is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MedCap AB (FRA:61MA) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of €48.24 is trading 1.1% below its estimated GF Value™ of €48.78. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for FRA:61MA:

  • Stock Based Compensation: €0.0 Mil
  • GF Value™: €48.78 vs. price of €48.24 (1.1% below fair value)
  • GF Score™: 81/100

No single metric tells the full story. See the FRA:61MA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MedCap AB Business Description

Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
81GF Score

Get the complete analysis for FRA:61MA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.24
Price
€48.78
GF Value